WHO Updates Essential Medicines List for Hemophilia and VWD: Louise Bannon Applauds Global Hematology Community’s Achievement
Louise Bannon, Director of Membership, Marketing and External Relations of ISTH, shared a post on LinkedIn:
”In today’s news!
WHO Updates Essential Medicines List to Improve Care for People with Bleeding Disorders
The World Health Organization (WHO) has updated its Essential Medicines List (EML) and Essential Medicines List for Children (EMLc) to better align with international clinical guidelines for the management of hemophilia and von Willebrand Disease (VWD).
These revisions will help ensure that decision makers worldwide are guided by the latest evidence when selecting and financing essential medicines, improving access to safer and more effective therapies for people with bleeding disorders (PWBDs).
Key updates include:
- New medicines added: Bi-specific monoclonal antibody emicizumab; recombinant FVIII and FIX clotting factor concentrates (CFCs)
- Existing medicines upgraded: Plasma-derived FVIII and FIX CFCs and desmopressin moved from the complementary to the core list
- Medicines removed: Pathogen-reduced and non-pathogen-reduced cryoprecipitate and Factor IX Complex (PCC)
Congratulations to the global hematology community for advocating strongly to achieve these revisions, ensuring that people with bleeding disorders have access to modern, safe, and effective therapies.
ISTH applauds the leadership of the World Federation of Hemophilia (WFH) and its partners for mobilizing this milestone effort and supporting equitable treatment access worldwide.”
Find the latest news in the World of Bleeding Disorders featured in Hemostasis Today.
-
Jan 30, 2026, 11:38Aaron Rodriguez Calienes on Intracranial Stenting: Rescue vs First-Line Outcomes
-
Jan 30, 2026, 11:25Ahmed Nasreldein on Sex Disparities in Thrombolysis Delay Among Egyptian Stroke Patients
-
Jan 30, 2026, 11:17Yanki Yarman: My PhD Project Has Been Published in Blood!
-
Jan 30, 2026, 11:08Alexandros Apostolou on Complications Associated with IDU and Thrombophilia
-
Jan 30, 2026, 10:57Peisong Ma on GRK5 Polymorphism Affecting Platelets
-
Jan 30, 2026, 10:47Ashok Yadav Explains Fetal Thrombotic Vasculopathy: FTV
-
Jan 30, 2026, 10:34Saif ur Rahman Compares K2 and K3 EDTA: Key Differences Explained
-
Jan 30, 2026, 10:22Manpreet Gill on Heparin Resistance: When 14 Years of Experience Finally Gets a Plot Twist
-
Jan 30, 2026, 10:14Mohamed Elsaid on The Role of Hyperlipidemia in Thrombogenesis